Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), being held May 31 – June 3, 2022, in Scottsdale, Ariz. A copy of the presentations will be made available on the Zynerba corporate website following the presentations at.

Oral Podium Presentation Details

• Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)     
  
• Date: Tuesday, May 31, 2022     
  
• Time: 4:20 p.m. MST (7:20 p.m. EDT)     
  
• Location: Fairmont Scottsdale Princess, Scottsdale, Ariz.     
  

Poster Presentation Details

• Title: RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX (ZYN2-CL-016) Completed During SARS-COV-2 Pandemic
• Date: Wednesday, June 1, 2022
• Time: 11:15 a.m. – 1:00 p.m. MST (2:15 p.m. – 4:00 p.m. EDT)
• Location: Fairmont Scottsdale Princess, Scottsdale, Ariz.

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11.2 deletion syndrome.